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INTRODUCTION
Central pontine myelinolysis (CPM) is an acute, non-inflam-
matory demyelinating disease of the pons of the central ner-
vous system (CNS) (1). The etiology and the pathogenesis of
CPM remain unclear, but too-rapid correction of hyponatrem-
ia is often associated with CPM, which is the result of the selec-
tive loss of myelin. Other risk factors identified include alco-
holism, malnutrition, liver disease, and interestingly, liver
transplant (2, 3). Only one prior case report of subjects asso-
ciated with CPM and hepatic veno-occlusive disease after allo-
geneic hematopoietic stem cell transplantation (HSCT) has
been published (4).
We describe a rare case who developed CPM after allogene-
ic HSCT for acute lymphoblastic leukemia (ALL).
CASE REPORT
A 37-yr-old man was admitted to our hospital for HSCT.
He was diagnosed with ALL, presenting with mild fever, fa-
tigue, and headache. A bone marrow examination showed acute
precursor B cell leukemia with morphology consistent with
FAB L2 subtype. Cytogenetic study demonstrated a clonal
abnormality with translocation between chromosomes 9 and
22. BCR/ABL rearrangement was positive by fluorescence in
situ hybridization (78.5%). The patient received initial induc-
tion chemotherapy, which was composed of vincristine 2 mg
on days 1 and 8, daunorubicin 90 mg/m2/day on days 1-3,
prednisolone 60 mg/m2/day on days 1-14, and imatinib 600
mg once daily from day 8 with intrathecal methotrexate. He
achieved morphological remission. Since an HLA-matched
sibling donor was available, allogeneic HSCT was performed
with the matched sibling donor.
Following a conditioning regimen of busulfan 0.8 mg/kg/
dose four times daily on days -8, -7, -6, -5 and cytoxan 60 mg/
kg/day on days -3, -2, the patient received 9.23×108 nucle-
ated cells/kg (10.4×106 CD34 cells/kg) from his brother. For
prophylaxis of graft-versus-host disease (GVHD), cyclosporine
and prednisolone were used. He tolerated this conditioning
therapy well, and the post-transplant course was unremark-
able until the 12th day. The patient showed altered mentality
on the 13th day, and his serum cyclosporine level was increased
higher than 1,300 ng/mL (normal range, 150-300 ng/mL).
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Central Pontine Myelinolysis in a Patient with Acute Lymphoblastic
Leukemia after Hematopoietic Stem Cell Transplantation:
A Case Report
We describe a 37-yr-old man who developed central pontine myelinolysis (CPM) after
allogeneic hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic
leukemia. After HSCT, desquamation developed on the whole body accompanied
by hyperbilirubinemia. The liver biopsy of the patient indicated graft-versus-host dis-
ease-related liver disease, and the dose of methylprednisolone was increased. Then,
the patient developed altered mentality with eye ball deviation to the left, for which
electroencephalogram and magnetic resonance imaging (MRI) scans were done.
Brain MRI scan demonstrated the imaging findings consistent with central pontine
myelinolysis and extrapontine myelinolysis. He did not have any hyponatremia episode
during hospitalization prior to the MRI scan. To the best of our knowledge, presen-
tation of CPM after allogeneic HSCT is extremely rare in cases where patients have
not exhibited any episodes of significant hyponatremia. We report a rare case in which
hepatic dysfunction due to graft-versus-host disease has a strong association with
CPM after HSCT.
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As his altered mentality was attributed to cyclosporine-induc-
ed agitation and psychosis, we stopped administering cyclos-
porine and replaced cyclosporine with methylprednisolone.
Thereafter, the patient showed much improvement in con-
sciousness. On the 25th day, the patient developed desqua-
mation at whole body and hyperbilirubinemia with a peak
bilirubin level of 29 mg/dL. To rule out the possibility of
veno-occlussive disease (VOD), doppler ultrasonography was
conducted, which revealed no evidence of VOD. Then, trans-
jugular liver biopsy was done. Liver biopsy revealed vacuo-
lated cytoplasm and hyperchromasia of the bile duct epithe-
lium, which was compatible with GVHD (Fig. 1). Therefore,
we conducted high-dose steroid pulse therapy for 6 days and
maintained methylprednisolone 2 mg/kg/day since then.
On the 48th day, the patient demonstrated drowsy con-
sciousness with Glasglow Coma Scale E4M1V1 and left eye-
ball deviation. We conducted cerebrospinal fluid (CSF) tap-
ping and a brain MRI scan. CSF cytology was negative for
malignant cells, and the brain MRI scan showed multiple
white matter low densities (Fig. 2), which meant a nonspe-
cific result with respect to his neurologic problem.
At that time, the patient had a decreased urine output and
increased serum blood urea nitrogen (BUN)/Creatinine (Cr)
level. The ranges of serum BUN (normal range, 10-26 mg/
dL) and Cr level (normal range, 0.7-1.4 mg/dL) were 125-
165 mg/dL, 2.3-4.3 mg/dL respectively. To rule out the pos-
sibility of uremic encephalopathy, he received hemodialysis
three times per week from the 53th day. Thereafter, the BUN
and Cr level were maintained around 96-120 mg/dL, 1.5-
3.3 mg/dL respectively (Fig. 3).
During these treatments, the patient’s consciousness was
unchanged, so we followed up with CSF tapping, electroen-
cephalogram, and a brain MRI scan on the 70th day. CSF
cytology was negative, and the electroencephalogram find-
ing showed low amplitude theta slowings at all leads, which
meant diffuse cerebral dysfunction (Fig. 4). The follow-up
brain MRI revealed diffuse marked progression of confluent
Fig. 1. Needle biopsy of the liver. The GVHD here is affecting the
liver and marked by bile duct damage (hematoxylin and eosin
stain, ×400).
Fig. 2. Brain MRI reveals nonspecific findings including multiple
white matter low densities.
Fig. 4. Low amplitude theta slowings at all leads on electroen-
cephalogram indicate diffuse cerebral dysfunction.
Fig. 3. Serial changes of BUN and Cr.
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white matter T2 high-signal lesions in periventricular white
matter, basal ganglia, pons, and cerebellum, which was con-
sistent with CPM and extrapontine demyelinolysis (Fig. 5).
A review of serial serum sodium levels revealed that though
serum sodium measurements (normal range, 135-145 mEq/L)
had fluctuated between 128-150 mEq/L during 20 days of
hospitalization prior to follow-up MRI scan, there was no
episode of correcting hyponatremia in our patient.
On the 48th day, the serum sodium level was 145 mEq/L
and daily variations of serum sodium level were within the
range of 3-7 mEq/L/day since then. Also, the range of serum
osmolarity (normal range, 289-302 mOsm/kg) was 328-339
mOsm/L (Fig. 6). During the same period, cyclosporine as
another risk factor was not used any longer since the 14th
day.
The patient was given plasmapheresis three times per week
and steroid therapy as the experimental treatment of CPM,
but its effectiveness was insignificant. He died of bilateral intra-
ventricular hemorrhage on the 78th day.
DISCUSSION
CPM is a clinical syndrome including disturbances of con-
sciousness, disturbed function of caudal cranial nerves with
signs of pseudobulbar palsy, dysarthria as well as spastic para-
paresis and tetraparesis of various degrees of severity, epilep-
tic seizures, and hypotension (5-7).
A clinical diagnosis of CPM can be made, if patients suf-
fering from chronic alcoholism, electrolyte disturbance, or other
chronic diseases as well as liver transplant patients presenting
with massive mental changes show specific neuroradiological
findings on MRI scan (2). There is no treatment of choice in
CPM.
CPM has been known to result from the rapid correction
of hyponatremia and merge as a well-recognized neurologi-
cal complication following hepatic dysfunction such as chron-
ic liver disease and liver transplant (6, 8). In one series of post-
mortem examinations of liver transplant patients, a 29% inci-
dence of CPM was reported (9). It has been revealed that the
use of cyclosporine following liver transplant increases the risk
of development of CPM (10).
Neurological deterioration was a prominent feature of our
patient’s post-transplant course. In such a critically ill patient,
it is likely that several factors contributed to his encephalopa-
thy, including liver dysfunction, uremia, cyclosporine, and
CPM.
Other causes of encephalopathy in the setting of HSCT in-
clude electrolyte disturbances, cerebrovascular events or infec-
tion, and sedative drugs; but laboratory parameters and imag-
ing findings did not support a role for these possibilities in this
case.
Despite the likely multifactorial etiology of the encephalopa-
thy, the clinical signs of left eyeball deviation and the loss of
consciousness in conjunction with suggestive neuroimaging
are best explained by the diagnosis of CPM.
To the best of our knowledge, presentation of CPM after
allogeneic HSCT is extremely rare in cases where patients have
not exhibited any episodes of significant hyponatremia. Only
one case was reported that severe hepatic VOD and cyclosporine
therapy after HSCT induced the development of CPM with-
out any episodes of significant hyponatremia (4).
Given the known association with liver disease as the cause
of CPM, we concluded that our patient’s severe hepatic dys-
function due to GVHD might have predisposed him to the
development of CPM.
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